ACADIA Pharmaceuticals Inc. and Neuren Pharmaceuticals Ltd (NEU) have entered into an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome and other indications. Neuren retains rights to develop and commercialize trofinetide for all indications outside of North America. Neuren will receive US $10 million upfront plus potential milestones of up to US $455 million and royalties
http://crweworld.com/article/news-p...ercialization-of-trofinetide-in-rett-syndrome
Ann: Neuren and ACADIA announce agreement for North America, page-4
-
- There are more pages in this discussion • 493 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.71 |
Change
-0.260(1.30%) |
Mkt cap ! $2.523B | |||
| Open | High | Low | Value | Volume |
| $19.96 | $19.96 | $19.69 | $2.546M | 128.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 352 | $19.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.72 | 570 | 12 |
View Market Depth
| Last trade - 14.27pm 05/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |